Impact of the COVID-19 pandemic on the incidence of dengue fever in Peru

Rubí Plasencia-Dueñas1,2 | Virgilio E. Failoc-Rojas3 | Alfonso J. Rodriguez-Morales4,5

1Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional Pedro Ruiz Gallo, SOCIEM UNPRG, Lambayeque, Peru
2Facultad de Medicina, Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru
3Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru
4Grupo de Investigación Biomédica, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia
5Master of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, Universidad Científica del Sur, Lima, Peru

Correspondence
Virgilio E. Failoc-Rojas, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Av La Fontana 501, La Molina 15024, Lima, Peru.
Email: virgiliofr@gmail.com

Abstract
Dengue virus and severe acute respiratory syndrome coronavirus 2 coexist in dengue-endemic countries; therefore, the adoption of preventive measures is essential to control the spread of both viruses. We conducted an ecological study to compare the temporal patterns of the incidence of dengue before and during the Coronavirus disease 2019 (COVID-19) pandemic in Peru. A time-series analysis comparing the incidence of dengue using a Student’s t test with variance correction was performed. Poisson regression was applied to determine the incidence rate ratio (IRR) of dengue before and during the COVID-19 pandemic. The incidence of dengue was found to be increased in all endemic regions of Peru during the COVID-19 pandemic, with the highest incidences registered in Ica (IRR = 90.14), Huánuco (IRR = 38.6), and Ucayali (IRR = 23.78), with the exception of Piura (IRR = 0.83). The highest increases in the number of dengue cases per million inhabitants were in Ucayali (393.38), Tumbes (233.19), Ica (166.08), and Loreto (129.93). The gradient of dengue cases was positive in all endemic regions during the COVID-19 pandemic. The number of dengue cases per million increased during the COVID-19 pandemic throughout Peru and in several endemic regions, with the exception of Piura.

KEYWORDS
COVID-19, dengue, interrupted time series analysis, Peru, SARS-CoV-2

1 | INTRODUCTION

Dengue is the most important mosquito-borne viral infection. It causes 400 million cases of dengue fever worldwide every year. In the word, most cases are mild or asymptomatic, and only 100 million cases are clinically symptomatic, of which half a million require hospitalization.1 Dengue can be misdiagnosed as other febrile illnesses, resulting in an underestimation of the actual number of cases.2 As there is no specific treatment for this disease, only early diagnosis and access to immediate medical attention allow for the timely management of the disease, thereby preventing its progression to a serious stage and/or death.1

Due to epidemics, other public health issues such as dengue have been neglected in Peru due to the excessive prioritization of the prevention and control of these new diseases.3,6 In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2).5 The Americas have reported the highest number of cases to date.4 However, Latin America and the Caribbean continue to experience dengue epidemics that cause a large medical, human, and economic burden, which is why they should not be ignored.7

Currently, both viruses coexist in dengue-endemic countries, and it may be difficult to differentiate one from the other because both diseases share identical clinical symptoms,8 and laboratory results.9 The trends of COVID-19 and dengue analyzed in other countries have allowed us to reflect upon the relevance of adopting preventive measures necessary to control the spread of both diseases8,10–12 The purpose of this study was to compare the temporal pattern of dengue incidences before and during the COVID-19 pandemic in Peru.
2 METHODS

2.1 Study design

An ecological study was conducted using secondary data sources.

2.2 Geographical area of the study

Data on dengue and COVID-19 cases were assessed in 23 regions of Peru that have reported dengue cases in the past 3 years as an analysis unit, of which only the regions defined as endemic by the Ministerio de Salud del Perú (Ministry of Health of Peru)—such as Loreto, Amazonas, Ucayali, Junin, Tumbes, Huánuco, Piura, and Lambayeque—and not endemic as Ica were considered (see Supporting Information Figure).

2.3 Data sources

Data on the number of dengue cases were obtained from the virtual Health Situation Room of the Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, CDC, Peru (National Center for Epidemiology, Prevention and Disease Control, CDC, Peru) (available at https://www.dge.gob.pe/salasituacional/). This database contains the updated epidemiological information necessary to understand the healthcare situation and trends of diseases subject to epidemiological surveillance to guide, prioritize, and focus healthcare interventions by national, regional, and local authorities for the control of the health problems identified.

2.4 Procedures

Several databases were constructed using Microsoft Excel for each of the studied regions, as well as a database containing data from all Peruvian territories. The date of notification of cases was taken into account to determine the epidemiological weeks of COVID-19, and each was estimated using STATA® 16.0 and Microsoft® Excel. The COVID variable was regarded as a variable consisting of two values, which allowed for the division of time into two stages: before and during the COVID-19 pandemic. The population variable was determined based on population data estimated for each year in Peru and in each region, according to the Instituto Nacional de Estadística e Informática (National Institute of Statistics and Informatics or INEI, Spanish acronym). The variable “number of dengue cases per epidemiological week” in each region and in Peru was calculated as the annual number of dengue cases registered in the virtual Health Situation Room of the Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, CDC, Peru, expressed as a real number for each epidemiological week from 2015 to 2020. Cases per million were calculated based on the variable “dengue cases per epidemiological week” and taking into account the estimated population in Peru and in each region. The temperature and humidity variables were determined based on the data available for each region, calculating the mean temperature and humidity of each station by epidemiological week, according to the Servicio Nacional de Meteorología e Hidrología del Perú (National Service of Meteorology and Hydrology or SENAMHI, Spanish acronym). The data are available on the website: https://www.senamhi.gob.pe/?%26p=estaciones

2.5 Statistical analysis

Epidemiological weeks were converted into time series to analyze the time series of Peru and of each endemic region. A white noise test was performed to assess the randomness of the time series. The Kendall Tau test was performed to determine whether the series is stationary. The partial autocorrelation function was used to determine the existence of any temporal dependence of the number of dengue cases at a given time as opposed to previous periods. To estimate the average incidence of dengue (cases per million) before and during the COVID-19 pandemic, Student’s t test was used with correction of variances, and Poisson regression was applied to compare the incidence of dengue before and during the COVID-19 pandemic, obtaining an incidence rate ratio (IRR) crude and IRR adjusted for temperature and humidity. Moreover, 95% confidence intervals (CIs) and p values were calculated.

2.6 Ethical aspects

This study did not require the approval of an ethics committee as it was an analysis of secondary aggregate data obtained from an open-access public domain that does not allow for the identification of the cases assessed.

3 RESULTS

In 2020, the total number of dengue cases was 895 in the department of Amazonas, 1776 in Huánuco, 4256 in Junín, 10 829 in Lambayeque, 7126 in Ica, and 38 879 nationwide. The number of dengue cases per million increased during the COVID-19 pandemic throughout Peru as well as in several endemic regions, with the exception of Piura, where it decreased. The incidence of dengue has increased during the COVID-19 pandemic in all dengue-endemic regions of Peru, showing a greater increase in Huánuco (IRR = 58.3, 95% CI: 46.26–73.47), Ica (IRR = 53.93, 95% CI: 48.27–60.25), and Ucayali (IRR = 30.66, 95% CI: 28.56–32.92). However, adjusting for temperature and humidity, Ica is the region with the highest increase (adjusted IRR = 90.14, 95% CI: 80.60–100.81), Piura showed the lowest increase in incidence (adjusted IRR = 0.7, 95% CI: 0.59–0.83) and adjusting for temperature and humidity, (adjusted IRR = 0.83, 95% CI: 0.70–0.98). These results are statistically significant (p < 0.001,
We observed that since the first case of COVID-19 was reported in Peru, there has been a decrease in the number of dengue cases reported in several endemic regions of Peru. This temporal pattern is consistent with findings in Brazil.\textsuperscript{15} This could be due to the fact that the epidemiological alert triggered by an increase in the number of COVID-19 cases in Peru has affected the epidemiological surveillance of dengue, resulting in an underreporting of dengue cases, as has also occurred in recent epidemics, where the excessive prioritization of the prevention and control of emerging diseases has led to the unintentional neglect of endemic diseases.\textsuperscript{4} Dengue virus is transported mainly by infected travelers.\textsuperscript{1} Therefore, social isolation, quarantine, and other preventive measures that were implemented in Peru to counteract the progression of COVID-19 could have generated a real decrease in the incidence of dengue.\textsuperscript{11,15} In contrast, difficulty in access to timely diagnosis together with the population’s concern about the risk of being infected with COVID-19 in healthcare facilities may be another reason for the decrease in the number of dengue cases reported at the beginning of the COVID-19 pandemic.\textsuperscript{16}

Similarly, until July 2020, in the West Pacific region, countries such as China, Malaysia, Vietnam, and Australia registered fewer cases of dengue compared with that in the same period in 2019.\textsuperscript{17} Moreover, in the Americas, data registered up to epidemiological week 21, 2020, show a reduction by approximately 10% compared with that in 2019.\textsuperscript{18} Countries such as Bolivia, Honduras, Mexico, Paraguay, and Brazil reported a large increase in the number of dengue cases during the first weeks of 2020,\textsuperscript{11,15,19} which abruptly decreased subsequently, coinciding with the exponential increase in the number of COVID 19 cases.\textsuperscript{11,15}

The findings of our study also demonstrate that the number of dengue cases per million inhabitants during the COVID-19 pandemic

### TABLE 1: Incidence of dengue and cases per million inhabitants during the COVID-19 pandemic in endemic regions of Peru

| Region   | Pre-COVID-19\textsuperscript{a} | COVID-19\textsuperscript{a} | IRR crude | 95% CI crude | IRR adjusted\textsuperscript{b} | 95% CI adjusted |
|----------|---------------------------------|-----------------------------|-----------|--------------|-------------------------------|-----------------|
| Amazonas | 7.84                            | 41.25                       | 5.25*     | 4.64–5.94    | 5.39*                         | 4.75–6.12       |
| Huánuco  | 0.87                            | 50.99                       | 58.3*     | 46.26–73.47  | 38.6*                         | 30.47–48.90     |
| Junín    | 7.39                            | 61.12                       | 8.2*      | 7.67–8.77    | 10.15*                        | 9.43–10.93      |
| Loreto   | 59.16                           | 129.93                      | 2.18*     | 2.10–2.25    | 2.17*                         | 2.10–2.25       |
| Piura    | 2.8                             | 1.94                        | 0.7*      | 0.59–0.83    | 0.83*                         | 0.70–0.98       |
| Tumbes   | 33.18                           | 233.19                      | 6.91*     | 6.42–7.46    | 6.25*                         | 5.75–6.80       |
| Ucayali  | 12.68                           | 393.38                      | 30.66*    | 28.56–32.92  | 23.78*                        | 21.66–26.10     |
| Lambayeque | 6.21                         | 7.86                        | 1.26*     | 1.12–1.41    | 2.17*                         | 1.89–2.50       |
| Ica      | 3.04                            | 166.08                      | 53.93*    | 48.27–60.25  | 90.14*                        | 80.60–100.81    |
| Peru     | 8.22                            | 32.60                       | 3.93*     | 3.87–3.99    | -                             |                 |

Abbreviations: 95% CI, 95% confidence interval; IRR, incidence rate ratio.

\textsuperscript{a}Dengue cases per million inhabitants.

\textsuperscript{b}Adjusted for temperature and humidity.

\(p < 0.001; \quad **p = 0.029.\)
FIGURE 1  Number of dengue cases per epidemiological week from January 2018 to December 2020 in nine endemic regions of Peru and nationwide. (A) Amazon. (B) Huanuco. (C) Loreto. (D) Piura. (E) Junin. (F) Tumbes. (G) Ucayali. (H) Lambayeque. (I) Ica. (J) Peru. The vertical black dotted line corresponds to the first case of COVID-19 reported in Peru, dividing the time into two periods: before and during the COVID-19 pandemic.
has exceeded the number of cases reported in the years before the pandemic. This is in line with findings in other geographical areas such as Brazil, the Southwest Indian Ocean Islands, and Asia. Paradoxically, this could also be explained because of the prevention measures established to prevent COVID-19 transmission because, during the quarantine, populations have lived in close contact with each other for a long time, which promotes the reproduction of arthropods/mosquitoes in and around the houses.

Aedes aegypti is found in 22 of the 24 regions of Peru, due to population migration from endemic areas and social determinants such as unplanned urban growth, deficient provision of basic services such as drinking water, housing development, and poverty conditions that make vector control increasingly difficult. The reduction of vector control measures, the suspension of preventive campaigns, and fumigations may have resulted in an increase in the number of cases during the COVID-19 pandemic. Moreover, some populations believe that fumigation can favor the spread of COVID-19, and for fear of contagion, do not allow health authorities to apply this vector control measure, resulting in a higher risk for dengue.

Previous studies found difficulties in the correct diagnosis of dengue and COVID-19 cases because both diseases share similar clinical symptoms, which is why co-infection in endemic areas is very likely to occur. An increase in the incidence of dengue and other arboviral diseases poses a real threat during the COVID-19 pandemic because it could lead to the overburdening of health systems.

During the Phenomenon Niño Costero 2017 in Peru, Piura was the region that reported 64% of all dengue cases nationwide, being the region with the highest incidence rate in the country. This generated a high natural immunization of its population, which could explain the decrease in the incidence of dengue in the following years, even during the COVID-19 era. In addition, Piura is the only region where DENV-2 and DENV-3 are circulating, although all four dengue serotypes are currently circulating throughout the country, with DENV-1 and DENV-2 circulating in the regions of Loreto, Ucayali, Tumbes, and Lambayeque, and only DENV-2 in Junín and Huánuco.

The limitations of this study mainly relate to Peru having a passive surveillance system, and therefore, the results could have a selection bias, which could result in their underestimation. Furthermore, being an ecological study, no inferences can be made at the individual level (ecological fallacy).

In conclusion, the number of dengue cases per million has increased during the COVID-19 pandemic throughout Peru and in several endemic regions, with the exception of Piura, where it has decreased. The entire country has experienced an increased incidence during the COVID-19 pandemic compared with the incidence before the COVID-19 pandemic. However, Huánuco, Ica, and Ucayali are the regions with the highest increase. Co-epidemics of COVID-19 and dengue in endemic areas, especially in Latin America and Southeast Asia, constitute a health, economic, and social burden. Therefore, it is important to apply vector control measures in conjunction with those established to prevent COVID-19, as well as measures that allow for the timely and adequate deployment of health personnel.

**CONFLICT OF INTERESTS**
The authors declare that there are no conflict of interests.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available in the public domain in the National Center for Epidemiology, Prevention and Disease Control, CDC, Peru (available at https://www.dge.gob.pe/salasituacional/) and Servicio Nacional de Meteorología e Hidrología del Perú (National Service of Meteorology and Hydrology or SENAMHI, Spanish acronym) available on the website https://www.senamhi.gob.pe/?%26p=estaciones

**ORCID**
Virgilio E. Failoc-Rojas http://orcid.org/0000-0003-2992-9342

**REFERENCES**

1. WHO. Dengue and severe dengue [sede Web]. Washington D.C., USA; 2020. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. Accessed August 18, 2020.

2. Waggoner JJ, Gresh L, Vargas MJ, et al. Viremia and clinical presentation in Nicaraguan patients infected with zika virus, chikungunya virus, and dengue virus. Clin Infect Dis. 2016;63(12):1584-1590.

3. Ledermann DW. El hombre y sus epidemias a través de la historia. Revista chilena de infectología. 2003;20:13-17.

4. Caylà JA. Epidemias mediáticas: una reflexión para la salud pública. Gac Sanit. 2009;23:362-364.

5. Organización Mundial de la Salud. COVID-19: cronología de la actuación de la OMS. [sede Web]. Washington. [Última actualización: 29 de enero de 2021; acceso: 10 de febrero de 2021]. Disponible en: https://www.who.int/es/news/item/29-06-2020-covidtimeline

6. WHO. Coronavirus Disease (COVID-19) Dashboard. [sede Web]. Washington, DC; 2021. Accessed February 10, 2021. https://covid19.who.int/
7. Esparza J. Epidemias y pandemias virales emergentes: ¿Cuál será la próxima? Invest Clin. 2016;57:231-235.
8. Dash N, Rose W, Nallasamy K. India’s lockdown exit: are we prepared to lock horns with COVID-19 and dengue in the rainy season? Pediatr Res. 2020;89:1047-1048.
9. Miah MA, Husna A. Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: a serious health concern. J Med Virol. 2020;93:161-162. https://doi.org/10.1002/jmv.26269
10. Din M, Asghar M, Ali M. COVID-19 and dengue coepidemics: a double trouble for overburdened health systems in developing countries. J Med Virol. 2020;93:601-602. https://doi.org/10.1002/jmv.26348
11. Mascarenhas MDM, Batista FMA, Rodrigues MTP, Barbosa OAA, Barros VC. Simultaneous occurrence of COVID-19 and dengue: what do the data show? Cad Saude Publica. 2020;36(6):e00126520.
12. Cardona-Ospina JA, Arteaga-Livias K, Villamil-Gómez WE, et al. Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. J Med Virol. 2020;93:522-527.
13. Valderrama B. Situación de dengue en el Perú a la semana 53. 2020. 29(53):753–761.
14. Lu L, Lin H, Tian L, Yang W, Sun J, Liu Q. Time series analysis of dengue fever and weather in Guangzhou, China. BMC Public Health. 2009;9:395.
15. Lorenz C, Dias Bocewicz AC, Corrêa de Azevedo Marques C, et al. Have measures against COVID-19 helped to reduce dengue cases in Brazil? Travel Med Infect Dis. 2020;37:101827.
16. Olive MM, Baldet T, Devillers J, et al. The COVID-19 pandemic should not jeopardize dengue control. PLOS Neglected Trop Dis. 2020;14(9):e0008716.
17. WHO. Update on the Dengue situation in the Western Pacific Region [sede Web]. 2020 [UpDate el 13 August 2020; acceso el 18 de August 16, 2020]. https://www.who.int/docs/default-source/emergency/surveillance/dengue-20200813.pdf?sfvrsn=fc80101d_38
18. Guzmán J. Situación Epidemiológica de dengue en el Perú, a la SE 52. 2017;26(52):1628-1630.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Plasencia-Dueñas R, Failoc-Rojas VE, Rodríguez-Moraes AJ. Impact of the COVID-19 pandemic on the incidence of dengue fever in Peru. J Med Virol. 2022;94:393-398. https://doi.org/10.1002/jmv.27298